Investigating the effects of glucose-lowering and immunosuppressive therapies on immune response in diabetes and kidney disease
Evaluating the Effect of Hemodialysis Modality and New Anti-glycemic Drugs on NETosis on in Hemodialysis and Diabetic Patient, and Assessment of NETosis in Various Kidney Diseases
This study is testing if new diabetes medications can lower harmful immune responses in people with diabetes and kidney disease to help prevent serious complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Western Galilee Hospital-Nahariya Government |
| Locations | 1 site (Nahariya) |
| Trial ID | NCT06821919 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the impact of new glucose-lowering medications, such as SGLT2 inhibitors and GLP-1 receptor agonists, on reducing NETosis in diabetic patients, which may help prevent complications like cardiovascular disease and kidney damage. Additionally, it will assess the effects of immunosuppressive therapies on NETosis in patients with immune-mediated kidney diseases, such as ANCA-associated vasculitis. By correlating NETosis activity with disease progression and treatment response, the study seeks to identify potential therapeutic strategies to improve clinical outcomes in both diabetes and chronic kidney disease.
Who should consider this trial
Good fit: Ideal candidates include diabetic patients aged 18 and older who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists, as well as chronic kidney disease patients with immune-mediated conditions.
Not a fit: Patients with acute infections, hematologic or oncologic diseases, or those who are positive for HIV or Hepatitis B/C may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of diabetes and kidney disease, reducing complications and enhancing patient quality of life.
How similar studies have performed: While the specific approach of this study is novel, previous studies have indicated that targeting NETosis may have beneficial effects in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: DM therapy study: - Diabetic patients aged 18 years or older (men and women). * Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists. -Chronic kidney disease (CKD) patients :50 CKD patients with various etiologies. • Focus: * This part of the study will specifically evaluate immune-mediated kidney disease, such as ANCA-associated vasculitis, and the effects of immunosuppressive therapy on NETosis. • Exclusion Criteria: * Patients with acute infections, hematologic or oncologic diseases, or positive for HIV or Hepatitis B/C
Where this trial is running
Nahariya
- Galilee Medical Center — Nahariya, Israel (Recruiting)
Study contacts
- Study coordinator: Etty Kruzel-Davila, MD
- Email: ETTYK@gmc.gov.il
- Phone: 972-4-9107619
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.